Cooley, Baker McKenzie Steer Vaccine Deal Worth Up To $1.06B
GlaxoSmithKline said Monday it will sell its rabies and tick-borne encephalitis vaccines to biotechnology company Bavarian Nordic for up to €955 million ($1.06 billion) in a deal steered by Cooley LLP...To view the full article, register now.
Already a subscriber? Click here to view full article